Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of the local anesthetic lidocaine and vitamin B12 (typically in the form of cyanocobalamin or methylcobalamin). It is primarily developed and investigated by researchers at Qilu Hospital of Shandong University for the treatment of chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Lidocaine functions as a voltage-gated sodium channel blocker, providing immediate analgesic effects by inhibiting nerve conduction in the pelvic region. Vitamin B12 is included for its neuroprotective properties, aiming to repair damaged nerves and modulate neuropathic pain pathways that contribute to the persistence of CPPS. The treatment is typically administered via local injection, such as transperineal or intraprostatic routes, to provide targeted relief for patients who are refractory to conventional oral medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + vitamin B12.